Ocugen (OCGN) Expected to Announce Earnings on Wednesday

Ocugen (NASDAQ:OCGN) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.86 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:30 AM ET.

Ocugen Stock Up 8.5%

OCGN stock opened at $1.78 on Wednesday. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.85 and a quick ratio of 1.85. The stock has a market capitalization of $555.93 million, a P/E ratio of -8.09 and a beta of 3.49. Ocugen has a fifty-two week low of $0.52 and a fifty-two week high of $1.96. The business has a 50-day moving average of $1.51 and a 200-day moving average of $1.39.

Wall Street Analysts Forecast Growth

OCGN has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a report on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research report on Tuesday, January 20th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Ocugen presently has an average rating of “Hold” and an average target price of $7.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp increased its stake in shares of Ocugen by 193.6% during the 4th quarter. State Street Corp now owns 3,978,738 shares of the company’s stock worth $5,371,000 after purchasing an additional 2,623,361 shares during the last quarter. Marshall Wace LLP bought a new position in Ocugen during the fourth quarter worth about $3,417,000. Goldman Sachs Group Inc. increased its position in Ocugen by 2,256.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company’s stock worth $3,108,000 after buying an additional 2,204,765 shares during the last quarter. Renaissance Technologies LLC raised its stake in Ocugen by 485.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company’s stock valued at $2,296,000 after buying an additional 1,410,200 shares during the period. Finally, Millennium Management LLC raised its stake in Ocugen by 29.7% in the fourth quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock valued at $7,285,000 after buying an additional 1,234,268 shares during the period. Institutional investors own 10.27% of the company’s stock.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.